Arena Pharmaceuticals Names Neil as Board Chair, Ouzren as Director
17 February 2021 - - US-based Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) has appointed Garry Neil, MD as chair of the company's board of directors. Additionally, Nawal Ouzren has been appointed as a new board member, the company said.

Dr. Neil has served on our board of directors since February 2017. He serves as the chief scientific officer of Cerecor, Inc., a publicly held biotechnology company focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with life altering diseases, a position he has held since Cerecor's February 2020 merger with Aevi Genomic Medicine, Inc., a biotechnology company with the same focus, where Dr. Neil had served as chief scientific officer since September 2013.

Prior to joining Aevi Genomic Medicine, Dr. Neil was a Partner at Apple Tree Partners, a life science private equity firm, from September 2012 to September 2013, and held a number of senior positions in the pharmaceutical industry, including most recently as Corporate VP of Science and Technology at Johnson and Johnson from November 2007 to August 2012.

Prior to these roles, Dr. Neil served as Group president at Johnson and Johnson Pharmaceutical Research and Development, VP of R and D at Merck KGaA/EMD Pharmaceuticals, and VP of Clinical Research at AstraZeneca and Astra Merck.

Dr. Neil holds a BS from the University of Saskatchewan and an MD from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto.

Dr. Neil also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He served on the board of GTx, Inc., a publicly traded biopharmaceutical company focused on cancer and other serious medical conditions, until its merger with Oncternal Therapeutics in March 2019.

Dr. Neil is the Founding chairman of TransCelerate Biopharma, Inc., a non-profit pharmaceuticals industry R and D consortium, and a past member of the TransCelerate Board.

He also serves on the board of the Reagan Udall Foundation and previously served on the board of Foundation for the National Institutes of Health and on the Science Management Review board of the NIH.

Dr. Neil is also the past chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA Foundation Board.

Ouzren brings 20 years of leadership and expertise across a range of areas, including clinical development, operations, manufacturing, quality, and commercialization.

She currently serves as chief executive officer and Member of the board at Sensorion SAS (ALSEN.PA), a publicly traded biotechnology company based in Montpellier, FR. Prior to joining Sensorion, she served as Group vice president, Rare Genetic Diseases at Shire International GmbH.

In that role she led a cross-functional organization including clinical development, R and D, and global marketing. Before Shire, Ouzren held various positions at Baxalta from 2014 to June 2016 when Baxalta was acquired by Shire.

During her career, Ouzren also held roles of increasing responsibility across multiple functions at Baxter BioScience and General Electric. In addition to her board role at Sensorion, Ouzren serves on the board of Inventiva (Euronext Paris and NASDAQ: IVA), a clinical-stage biopharmaceutical company.

Ouzren holds a Master of Science Degree in Chemical Engineering from the Université de Technologie de Compiègne, France.